Your search for Warfarin returned 18 results

The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.

Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.

The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.

Dabigatran 150mg was superior to warfarin and dabigatran 110mg was noninferior to warfarin for preventing stroke in patients with atrial fibrillation (AF) regardless of CHA2DS2-VASc scores, as shown by the results of a subgroup analysis of the RE-LY trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Aspirin does not appear to reduce the risk of nonarteritic ischemic optic neuropathy development in men, according to data presented at the 2019 American Academy of Ophthalmology Meeting in San Francisco, CA.

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.

Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.

The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.